Blocking glycan production by targeting GALNT7 for prostate cancer therapy

2026/01/20 by Ziqian Peng, Kirsty Hodgson, Margarita Orozco-Moreno +1 · 1 voice
Biochemistry, Genetics and Molecular Biology · Immunology and Microbiology · #Glycosylation and Glycoproteins Research #Proteoglycans and glycosaminoglycans research #Galectins and Cancer Biology

paper · doi:10.1080/14728222.2026.2619761

openalex publication_date 2026/01/20 · openalex created_date 2026/01/21 · openalex updated_date 2026/07/15

Abstract

1. Prostate cancer is the second most diagnosed male cancer and is a leading cause of cancer related deaths [1]. Androgen receptor (AR) targeted therapies, including abiraterone, enzalutamide, daro...

Discussions

• Could GALNT7 be a promising therapeutic target for #ProstateCancer? A team led by Dr Jennifer Munkley @newcastleuni.bsky.social explores the enzyme's role & emerging strategies to inhibit its activit [bsky, 1 points, 0 comments]

Related

• GLP1 receptor agonism alters growth and therapeutic response in prostate cancer
• N-Glycans in cancer progression
• Androgen Receptor Drives Polyamine Synthesis, Creating a Vulnerability for Prostate Cancer
• Therapeutic Strategies to Target the Androgen Receptor
• Discovery of ARD-69 as a highly potent proteolysis targeting chimera (PROTAC) degrader of androgen receptor (AR) for the treatment of prostate cancer